Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
Primary Industries
- Drugs
- Pharmaceuticals
- Therapeutic
- Cancer
- Delivery
- Disease
- Gastrointestinal
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 8626
License Grant
Licensor hereby grants to Licensee a non-transferable sublicenseable royalty-bearing, exclusive right and license under the Licensed Technology to Exploit the Licensed Product in the Territory, to the full end of the Term for which the Licensed Technology is licensed, unless sooner terminated as herein after provided.
Technology licensed by a U.S. company to a U.S. company is an Oral Spray, which aims to prevent nausea and vomiting associated with chemotherapy and radiotherapy, as well as postoperative-induced nausea and vomiting. FDA recently agreed to review application for the spray. Note that the lower range of the royalty rate is estimated.
License Property
Licensor has certain proprietary rights and intellectual property (including to certain patents) with respect to lingual sprays for the metered delivery of pharmaceutical products to humans (the 'Technology').
'Licensed Technology' shall mean the Licensor's Patents, the Licensor Know-How and the Drug Master File, collectively, but only with respect to the Exploitation of the Licensed Product.
'Licensed Product(s)' shall mean any dosage of pharmaceutical composition or preparation in finished form labeled and packaged for sale by prescription, overthe-counter or any other method for human application only that contains ondansetron delivered by means of the Licensed Process.
Ondansetron lingual spray , or “OLS,†our most recently-acquired product candidate,is a novel delivery system that utilizes the vast and highly-absorptive surfaces of the oral cavity (including the area under the tongue) to deliver the drug ondansetron, the most widely used drug to prevent chemotherapy-induced nausea and vomiting , directly into the bloodstream. Administration of ondansetron lingual spray (i.e., spraying on the tongue) will potentially decrease the time necessary to ahcive effective concentrations in the bloodstream, which we believe will more rapidly alleviate nausea and vomiting than conventional oral tablet dosage forms of ondansetron currently available.
Field of Use
Ondansetron is a medication used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, or surgery.
IPSCIO Record ID: 328331
License Grant
Licensor hereby grants to Licensee a non-transferable, non-sublicenseable, royalty-bearing, exclusive sublicense under the Licensed Technology to Exploit the Licensed Product in the Territory, to the full end of the Term for which the Licensed Technology is licensed, unless sooner terminated as herein after provided; provided, however, that Licensee shall have the right to (i) utilize Third Parties to manufacture the Licensed Product in the Territory, and (ii) use, have used, manufacture or have manufactured the Licensed Product outside of the Territory solely for purposes of the distribution and sale of the Licensed Product inside the Territory. Licensee shall be entitled to use a Third Party contract sales organization to market the Licensed Product in the Territory; provided, that the employees of such Third Party contract sales organization that are utilized to market the Licensed Product are trained and managed by Licensee and carry only Licensee’s products.
In the event that Licensee elects to use the Licensed Trademark in connection with the Exploitation of the Licensed Product in the Territory, then a non-transferable, non-sublicenseable, royalty-bearing, non-exclusive right and license under the Licensed Trademark will be granted for the sole purpose of using the Licensed Trademark to market, distribute and sell the Licensed Product in the Territory, to the full end of the Term for which the Licensed Product is licensed, unless sooner terminated as herein after provided.
License Property
Licensor has exclusive, restricted sublicensable rights under a license from the owner of certain patents, intellectual property and know-how relating to lingual sprays for the metered delivery of pharmaceutical products to humans..
Licensed Product shall mean any dosage of pharmaceutical composition or preparation in finished form labeled and packaged for sale by prescription, over-the-counter or any other method only for human application that contains, as the sole active ingredient, the Designated Compound delivered by means of the Licensed Process.
US Patent No. 6,676,931 B2 – Buccal, polar and non-polar spray or capsule
Licensed Trademark shall mean “ZENSANA†owned by Licensor as evidenced by U.S. Trademark Application Serial No. 78,710,181.
Field of Use
Field of use is for the metered delivery containing ondansetron as an active ingredient that will be administered to humans.
Zensana (ondansetron hydrochloride) is an oral spray 5-HT3 antagonist formulation intended for the prevention of chemotherapy induced nausea and vomiting.
IPSCIO Record ID: 6941
License Grant
Licensor hereby represents and warrants that it has right to license the Licensor Technology, and grants to Korean Licensee an exclusive license and right, under the Licensor Technology, to manufacture, have manufactured, use, import, distribute and sell Licensed Products in the Field in the Territory during the Term. Notwithstanding the foregoing, Licensor retains the right to license or otherwise exploit other anti-emetic technologies and products in the Territory. Licensor shall provide reasonable cooperation to Licensee, as may be necessary or appropriate to support Licensee’s efforts, in order that Licensee may register such license and right with the relevant authorities in the Territory.
Licensor is the owner of certain technologies, know-how and/or patent rights relating to ondansetron oral spray. Licensee desires to obtain the right and License to use and exploit the above- referenced technologies, know-how and patent rights for the purpose of making and commercializing an ondansetron oral spray product. Licensor is willing to grant Licensee such a License pursuant to the terms and subject to the conditions set forth herein.
Licensed Product means an ondansetron oral spray composition, dosage form, or method of treatment (i) the manufacture, use or sale of which is covered by one or more claims of a Licensor Patent; or (ii) which is made or used, at least in part, utilizing Licensor Know-How.
Field of Use
Field means the making and selling of ondansetron oral spray as an anti-emetic for human use.
IPSCIO Record ID: 328330
License Grant
Licensor hereby grants to Licensee and Licensee accepts, a non-transferable, sublicenseable, royalty-bearing, exclusive right and license under the Licensed Technology to Exploit the Licensed Product in the Territory, to the full end of the Term for which the Licensed Technology is licensed, unless sooner terminated as herein after provided.
License Property
Technology shall mean with respect to lingual sprays for the metered delivery of pharmaceutical products to humans.
United States Patent No. 6,676,931 B2 – Buccal, polar and non-polar spray or capsule
Licensed Technology shall mean the Licensor Patents, the Licensor Know-How and the Drug Master File, collectively, but only with respect to the Exploitation of the Licensed Product.
Licensed Product shall mean any dosage of pharmaceutical composition or preparation in finished form labeled and packaged for sale by prescription, over-the-counter or any other method only for human application that contains, as the sole ingredient, the Designated Compound delivered by means of the Licensed Process.
Field of Use
Field of use is for the metered delivery of pharmaceutical products to humans.
IPSCIO Record ID: 57817
License Grant
On May 2, 2010, the Licensee received a worldwide, exclusive and perpetual license to use patents and know how relating to BEKINDAâ„¢ from the previous Licensor, a U.S. company, who is now out of business. On March 7, 2014, the Company entered into a licensing agreement with a U.S. University to secure certain patent rights related to the drug candidate. The Company therefore terminated the agreement with the U.S. company and licensed the patents directly from the U.S. university, the original owner of the patents. Under the agreement, the Company agreed to pay the U.S. university certain future payments.
License Property
BEKINDAâ„¢ is a once-daily controlled release oral formulation of ondansetron, a leading member of the family of 5HT-3 serotonin receptor inhibitors for the treatment of gastroenteritis and gastritis.
Gastroenteritis, also known as infectious diarrhea, is inflammation of the gastrointestinal tract—the stomach and small intestine.
Gastritis is inflammation of the lining of the stomach.
Field of Use
The biopharmaceutical company is focused on the development and acquisition of late clinical-stage, proprietary, orally-administered drugs for the treatment of inflammatory and gastrointestinal diseases and cancer.
1)
Gastroenteritis and gastritis – 24 mg strength
2)
Irritable Bowel Syndrome with Diarrhea (IBS-D) – 12 mg strength
3)
Prevention of chemotherapy and radiotherapy induced nausea and vomiting (oncology support) – 24 mg strength
IPSCIO Record ID: 222534
License Grant
Licensor grants an exclusive license, or sublicense, as the case may be, under the Licensor Patent Rights and Know-how, in each case with the right to grant sublicenses, to research, develop, make, have made, use, import, export, market, offer for sale, sell and have sold, Licensed Product in the Territory within the applicable Field.
License Property
The Compounds means SCH 619734 (Rolapitant) and SCH 900978.
The Licensed Product means any product comprising, incorporating or containing any Compound, or an alternate form of any Compound, including, but not limited to, a pharmaceutically acceptable salt, polymorph, crystal form, prodrug, or solvate of any Compound to the extent such alternate form is claimed in the Licensor Patent Rights.
Rolapitant, a Phase III-ready, oncology supportive-care product candidate, is a potent and selective neurokinin-1 (NK-1) receptor antagonist with an extended plasma half-life that has the potential to improve the management of nausea and vomiting experienced by cancer patients undergoing treatment with emetogenic chemotherapy. Phase II clinical testing of rolapitant for the prevention of nausea and vomiting in cancer patients treated with highly emetogenic chemotherapy demonstrated promising five-day activity following the administration of a single dose.
Field of Use
The Field means with respect to SCH 619734 (Rolapitant) all therapeutic, prophylactic, palliative and diagnostic uses in humans, and means, with respect to SCH 900978, treatment of nausea or vomiting of any cause; treatment of disease or treatment of symptoms or side effects of disease in oncology indications; treatment of side effects of oncology treatments or therapies; and (iv) any other supportive care indications in oncology.
IPSCIO Record ID: 221
License Grant
Licensor grants to Israeli Licensee an exclusive worldwide, perpetual license under the Patents and the Licensed Know-How for the sole purpose of developing, manufacturing, commercializing, making, using, selling, offering for sale and importing Products, in the Field of Use (the “Licenseâ€).
License Property
“Product†shall mean all extended release (including, but not limited to, 24 hour extended release) and all other Ondansetron tablet formulations, that infringe one or more claims of the Patents and Licensed Know How, including CDT® delivery technology.
Ondansetron is a serotonin 5-HT3 receptor antagonist used mainly as an antiemetic to treat nausea and vomiting, often following chemotherapy.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
